Efficacy and safety of moxidectin plus albendazole, moxidectin plus tribendimidine, and moxidectin alone versus albendazole plus oxantel pamoate against Trichuris trichiura and concomitant soil-transmitted helminth infections: a randomised controlled trial

Swiss Tropical and Public Health Institute0 个研究点目标入组 640 人开始时间: 2017年2月28日最近更新: 2020年10月19日

试验速览

•1. Written informed consent signed by participants (if 18 years old), parents and/or legal guardian; and oral assent by participants
•2. Able and willing to be examined by a study physician at the beginning of the study
•3. Able and willing to provide two stool samples, at the beginning (baseline) and approximately one and three weeks after treatment (follow-up)
•4. Positive for T. trichiura eggs in the stool
•5. Absence of major systemic illnesses (e.g. cancer, diabetes, clinical malaria or organ failure) as assessed by a medical doctor, upon initial clinical assessment
•6. No known or reported history of chronic illness as cancer, diabetes, chronic heart, liver or renal disease.
•7. No recent anthelminthic treatments (within past 2 months)
•8. No known allergy to study medications
•9. Age 12-18 years

•1. No written informed consent by participants, parents and/or legal guardian
•2. Presence of any abnormal medical condition judged by the study physician
•3. History of acute or severe chronic disease such as cancer, diabetes, chronic heart, liver or renal disease
•4. Recent use of anthelminthic drugs (within past 2 months)
•5. Attending other clinical trials during the study
•6. Negative diagnostic result for T. trichiura eggs in stool samples
•7. Age below 12 years

发起方

Swiss Tropical and Public Health Institute